KEQU Form 4: CEO/Director Sells 1,000 Shares at $43.09
Kewaunee Scientific director and President/CEO Thomas David Hull III reported a sale of 1,000 shares of the company's common stock on 10/01/2025 at a weighted average price of $43.09 per share, with the reported price range between $43.00 and $43.22.
Rhea-AI Filing Summary
Kewaunee Scientific director and President/CEO Thomas David Hull III reported a sale of 1,000 shares of the company's common stock on 10/01/2025 at a weighted average price of $43.09 per share, with the reported price range between $43.00 and $43.22. Following the sale, Mr. Hull beneficially owns 38,719 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. The filing includes a statement that the reporting person will provide, upon request, the number of shares bought at each separate price within the disclosed range.
Positive
- Timely disclosure of insider transaction via Form 4
- Clear pricing information with weighted average and price range provided
- Post-transaction beneficial ownership is reported (38,719 shares)
Negative
- Insider sale of 1,000 shares by the CEO/director
- No stated reason for the disposition provided in the filing
Insights
TL;DR: Insider sale of 1,000 shares reduces CEO/director stake to 38,719 shares; transaction appears routine, not clearly material.
The sale is modest in size relative to typical institutional positions and is disclosed with a weighted average price of $43.09 and a price range of $43.00–$43.22. The filing meets Section 16 disclosure requirements and provides willingness to supply trade-level detail. There is no additional context in the Form 4 about purpose or any derivative transactions, so implications for company operations or outlook are not specified in the filing.
TL;DR: The disclosure is compliant and clear; the sale is a standard insider disposition with limited apparent governance concern.
The Form 4 identifies the reporting person as both an officer and director and discloses the post-transaction beneficial ownership of 38,719 shares. Signature by an attorney-in-fact is properly provided. The document contains no indication of undisclosed related-party transactions, option exercises, or changes in control. Based solely on this filing, there are no immediate governance red flags, though investors may seek additional context outside this form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,000 | $43.09 | $43K |
Footnotes (1)
- F1. The price reflects the weighted average purchase price of the transactions reported. The price range of such transactions was $43.00 to $43.22. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares purchased at each separate price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KEQU insider Thomas David Hull III report on Form 4?
What price range was disclosed for the KEQU insider sale?
Who signed the Form 4 for the KEQU filing?
Does the Form 4 indicate any derivative or option transactions for KEQU?
AI-generated analysis. How Rhea-AI works. Not financial advice.